The SAUDI CLINICAL MANAGEMENT GUIDELINES FOR RENAL CELL CARCINOMA

National Cancer Center (NCC)
### List of Contributors

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>City</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdullah Alghamdi</td>
<td>Prince Sultan Military Medical City</td>
<td>Riyadh</td>
<td>Department of Urology</td>
</tr>
<tr>
<td>Sultan Alkhateeb</td>
<td>King Abdulaziz Medical City and King Saud bin Abdulaziz University for Health Sciences</td>
<td>Riyadh</td>
<td>Department of Surgery, Division of Urology</td>
</tr>
<tr>
<td>Khalid Alghamdi</td>
<td>Security Forces Hospital</td>
<td>Riyadh</td>
<td>Department of Surgery, Division of Urology</td>
</tr>
<tr>
<td>Shouki Bazarbashi</td>
<td>King Faisal Specialist Hospital and Research Center</td>
<td>Riyadh</td>
<td>Department of Oncology, Section of Medical Oncology, Oncology Center</td>
</tr>
<tr>
<td>Esam Murshid</td>
<td>Prince Sultan Military Medical City</td>
<td>Riyadh</td>
<td>Department of Oncology, Oncology Center</td>
</tr>
<tr>
<td>Mohammed Alotaibi</td>
<td>King Faisal Specialist Hospital and Research Center</td>
<td>Riyadh</td>
<td>Departments of Urology and Oncology</td>
</tr>
<tr>
<td>Ashraf Abusamra</td>
<td>King Khalid Hospital, King Abdulaziz Medical City, Ministry of National Guard Health Affairs</td>
<td>Riyadh</td>
<td>Department of Surgery, Urology Section</td>
</tr>
<tr>
<td>Danny Rabah</td>
<td>King Saud University</td>
<td>Riyadh</td>
<td>Department of Surgery, College of Medicine and Uro-Oncology Research Chair</td>
</tr>
<tr>
<td>Imran Ahmad</td>
<td>King Faisal Specialist Hospital and Research Center</td>
<td>Riyadh</td>
<td>Departments of Urology and Oncology</td>
</tr>
<tr>
<td>Mubarak Al-Mansour</td>
<td>King Abdulaziz Medical City and King Saud bin Abdulaziz University for Health Sciences</td>
<td>Jeddah</td>
<td>Department of Oncology</td>
</tr>
<tr>
<td>Ahmad Saadeddin</td>
<td>King Abdulaziz Medical City</td>
<td>Riyadh</td>
<td>Department of Oncology</td>
</tr>
<tr>
<td>Abdullah Alsharm</td>
<td>Comprehensive Cancer Center, King Fahad Medical City.</td>
<td>Riyadh</td>
<td>Department of Medical Oncology</td>
</tr>
</tbody>
</table>

*Corresponding author:*

Dr. Sultan Alkhateeb,
Department of Surgery, Division of Urology, King Abdulaziz Medical City, King Saud bin Abdulaziz University for Health Sciences, 
P.O. Box: 22490 (1446), 
Riyadh 11426, Saudi Arabia. 
E-mail: alkhateebsu@ngha.med.sa

Supportive team:-
Dr. Ahmed Alamry, MD, MHA, FRCPC
Secretary General
Saudi Health Council, Riyadh

Dr. Yagob Almazrou
Advisor at Saudi Health Council
Saudi National Cancer Center - Saudi Health Council, Riyadh

Dr. Suliman Alshehri
General Director for SNCC
Saudi National Cancer Center – Saudi Health Council, Riyadh
s.alshehri@shc.gov.sa

Ms. Rana Alqahtani, MPH, CPH
Public Health Specialist
Training and development
Saudi Health Council, Riyadh
R.alqahtani@shc.gov.sa
Disclosure of Benefit: All authors have no conflicts of interest; this work was not supported or funded by any drug company.

Author participation: All authors listed on this manuscript contributed significantly to the revision of literature, establishing the current guidelines, writing, and approving the final version of this manuscript.

The National Cancer Canter (NCC) at the Saudi health council (SHC) holds copyright for these materials. Please acknowledge authorship if you copy or disseminate them. The NCC-SHC would like to thank all those involved in preparation of these resources.
Abstract

This is an update to the previously published Saudi guidelines for the evaluation, medical, and surgical management of patients diagnosed with renal cell carcinoma (RCC). It is categorized according to the stage of the disease using the tumor node metastasis staging system 7th edition. The guidelines are presented with supporting evidence level, they are based on comprehensive literature review, several internationally recognized guidelines, and the collective expertise of the guidelines committee members (authors) who were selected by the Saudi Oncology Society and Saudi Urological Association upon the request and support of the National Cancer Center (NCC). Considerations to the local availability of drugs, technology, and expertise have been regarded. These guidelines should serve as a roadmap for the urologists, oncologists, general physicians, support groups, and healthcare policy makers in the management of patients diagnosed with RCC.

**Key Words:** Cancer, carcinoma, cell, guidelines, kidney, management, renal, Saudi Oncology Society, Saudi Urological Association
INTRODUCTION
Renal cancer represents the third common genitourinary cancer in Saudi Arabia after urinary bladder and prostate. It accounts for 3.4% of all male cancers and 2.0% of all female cancers. In 2010, a total of 167 cases were diagnosed in males and 117 cases in females. The age-standardized rate in males was 2.9/100,000 and in females was 2/100,000 populations.

All cases of renal cell carcinoma (RCC) should preferably see or discussed in a multidisciplinary forum.

1. PRETREATMENT EVALUATION
   1.1. Evaluation of suspicious renal mass:
      1.1.1. History and physical examination
      1.1.2. Blood count, renal, and hepatic profile
      1.1.3. Computed tomography scan of chest, abdomen, and pelvis
      1.1.4. Urine analysis
      1.1.5. Urine cytology should be done if urothelial cancer is suspected
      1.1.6. Indications of renal mass biopsy, suspicion of renal abscess, suspicion of metastases, suspicion of renal lymphoma, and prior to systemic therapy. Furthermore, strongly advocated before nonsurgical options (i.e., active surveillance, cry ablation, and radiofrequency ablation).
      1.1.7. Brain imaging and bone scan should be done only if clinically indicated.

2. STAGING
   The American joint commission on cancer staging tumor node metastasis 7th addition will be adopted [Appendix 1].

3. TREATMENT
   3.1 Localized disease (T1a):
      3.1.1. The recommended treatment is surgical excision preferably by partial nephrectomy (open, laparoscopic, or robotic) in all cases and especially in patients with solitary kidney, bilateral tumors, familial renal cell cancer, or renal insufficiency (evidence level-1 [EL-1]) [3-9]
      3.1.2. Radical nephrectomy (preferably laparoscopic) should be reserved for cases where partial nephrectomy is not technically feasible after consultation with an experienced surgeon (EL-1) [3-16]
      3.1.3. Nonsurgical options (i.e., active surveillance, cry ablation, and radiofrequency ablation) are all inferior to surgical excision in terms of oncological outcome and are not recommended except in patients with significant comorbidities that interdict surgical intervention (EL-2). [17-21]

   3.2 Localized disease (T1b)
      3.2.1. The recommended treatment is radical nephrectomy (preferably laparoscopic) (EL-1) [22-33].
      3.2.2. Partial nephrectomy may be an option, especially in a patient with a solitary kidney, bilateral tumors, familial renal cell cancer, or renal insufficiency. However, this should only be performed by experienced surgeon in a high-volume center (EL-1) [22-27]
      3.2.3. Nonsurgical options (i.e., active surveillance, cryoablation, and radiofrequency ablation) are not recommended.
3.3 Localized disease (T2)

3.3.1 The recommended treatment is radical nephrectomy (EL-1)\textsuperscript{[22-27]}

3.3.2 Partial nephrectomy and nonsurgical options (i.e., active surveillance, Cryoablation, and radiofrequency ablation) are not recommended.

3.4 Localized disease (T3)

3.4.1 The recommended treatment is radical nephrectomy with complete excision of all venous thrombus in the renal vein, inferior vena cava, and right atrium (EL-2)

3.4.2 These surgeries should only be performed in a tertiary care centers with the availability of cardiac, vascular or hepatic surgeon depending on the case (EL-2).\textsuperscript{[28,29]}

3.5 Excision of the ipsilateral adrenal gland

3.5.1 Ipsilateral excision of the adrenal gland during radical nephrectomy is indicated in upper pole kidney tumors or in the presence of a concurrent radiologically detectable Adrenal gland lesion (s) (EL-2).\textsuperscript{[30-33]}

3.6 Lymph node dissection

3.6.1 Resection of the regional lymph nodes (within Gerota’s fascia) is an integral part of radical nephrectomy.

3.6.2 Resection of the nonregional lymph nodes provides no therapeutic advantages and it is used for staging purposes (EL-1).\textsuperscript{[34]}

3.7 Partial nephrectomy when doing this surgery should aim to obtain adequate surgical margin and avoid tumor inoculation except in patients with Von Hippel–Lindau syndrome.\textsuperscript{[35-37]}

3.8 Postoperative follow-up after treatment we use the European Association of Urology Guidelines [Appendix 1].

3.9 Metastatic/advanced unrespectable disease:

3.9.1 Risk stratification for metastatic RCC

3.9.2 The Memorial Sloan-Kettering Cancer Center (MSKCC) risk classification for metastatic disease:\textsuperscript{[38]}

3.9.3 A Karnofsky performance status of <80%

3.9.4 Serum lactic dehydrogenase level >1.5 times the upper limit of normal

3.9.5 Corrected serum calcium >10mg/dL (2.5 mmol/L)

3.9.6 Hemoglobin concentration below the lower limit of normal

3.9.7 No prior nephrectomy (i.e., no disease-free interval)

3.9.8 Each of the above gives a score of one. Patients will be classified according to the total score as follow:

3.9.9 0: No risk factors: Good risk group

3.9.10 1, 2: Risk factors: Intermediate risk

3.9.11 3, 4, 5: Risk factors: High risk

3.9.12 Heng criteria validates component of the MSKCC with the addition of

3.9.13 Neutrophils greater than the upper limit of normal

3.9.14 Platelets greater than the upper limit of normal.\textsuperscript{[39]}

Several scenarios could be faced in patients with metastatic disease. Accordingly, the following should be considered:

3.9.15 Potentially resectable primary with solitary metastasis or multiple resectable lung metastasis: Those patients should undergo primary nephrectomy and
resection of the metastatic lesion/s (EL-2). Following complete resection no further therapy or “adjuvant therapy” is indicated (EL-3).

3.9.16 Potentially resectable primary and multiple nonresectable metastasis: Those patients should undergo resection of the primary tumor if in good performance status (EL-1), then should start systemic therapy according to the following guidelines:

3.9.16.1 Clear cell histology, good, and intermediate risk: Options of therapy include systemic therapy with either sunitinib (EL-1), bevacizumab and interferon-α-2a or pazopanib (EL-1). Highdose interleukin-2 in highly selected patients and centers.

3.9.16.2 Clear cell histology with poor risk: Temsirolimus is the preferred treatment (EL-1). Alternative options include sunitinib (EL-2).

3.9.16.3. Nonclear cell histology: Options of therapy include temsirolimus (EL-2), sunitinib (EL-2), or sorafenib (EL-2). Medullary and collecting duct carcinoma should be treated with platinum-based chemotherapy (EL-3).

3.9.17 Unresectable primary with or without metastatic disease: Those patients with good performance status should be offered systemic therapy according to their histology and MSKCC risk group as in item 4.8.2.

3.9.17.1 Recurrent disease post primary nephrectomy: Treatment will depend if resectable or not:

3.9.17.1.1 If resectable solitary metastasis: Surgical resection should be attempted (EL-2).

No systemic therapy is of benefit following complete resection (EL-3).

3.9.17.1.2 If nonresectable recurrence: Patient should be treated as metastatic disease according to their histology and MSKCC risk group and Heng criteria as in Item 3.9.1-3.

3.9.18 Second line therapy post tyrosine kinase inhibitors (TKIs) failure: Patients who fail 1st line TKI’s should receive second-line therapy if in reasonable performance status, options of second line agents include everolimus (EL-1) or axitinib (EL-1).

3.9.19 Third line: Consider everolimus.

Financial support and sponsorship Nil.

Conflicts of interest: There are no conflicts of interest.
REFERENCES


## Appendix 1: Surveillance following surgery adapted from European Association of Urology

<table>
<thead>
<tr>
<th>Risk profile</th>
<th>Treatment</th>
<th>Surveillance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>6 months</td>
</tr>
<tr>
<td>Low</td>
<td>RN/PN</td>
<td>US</td>
</tr>
<tr>
<td>Intermediate</td>
<td>RN/PN/cryoablation/RFA</td>
<td>CT</td>
</tr>
<tr>
<td>High</td>
<td>RN/PN/cryoablation/RFA</td>
<td>CT</td>
</tr>
</tbody>
</table>

CT: Computed tomography, RN: Radical nephrectomy, PN: Partial nephrectomy, RFA: radiofrequency ablation, US: Ultrasound